Related Experiment Video
Updated: Aug 13, 2026
09:29
The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies
Published on: February 12, 2015
Radiolabeled anti-lymphoma antibodies
G L DeNardo1, R T O'Donnell, S J DeNardo
1Molecular Cancer Institute, Hematology/Oncology, University of California, Davis Medical Center, 1508 Alhambra Boulevard, Room 3100, Sacramento, CA 95816, USA.
Cancer Chemotherapy and Biological Response Modifiers
|November 1, 2001
Summary
Advancements in understanding non-Hodgkin lymphoma (NHL) at the molecular level are paving the way for new treatments. Immunotherapy and radioimmunotherapy (RIT) show promise for relapsed or refractory NHL, with ongoing developments in antibody engineering and pretargeting strategies.
Area of Science:
- Oncology
- Immunology
- Radiopharmaceutical Science
Background:
- Non-Hodgkin lymphoma (NHL) remains a significant challenge, with its exact cause unknown.
- Recent molecular-level insights into genetic aberrations affecting apoptosis and proliferation are crucial for understanding NHL pathogenesis.
- Existing treatments for relapsed or refractory NHL have limitations, necessitating novel therapeutic approaches.
Purpose of the Study:
- To explore the implications of molecular insights for future NHL management.
- To review the progress and potential of immunotherapy and radioimmunotherapy (RIT) in NHL treatment.
- To discuss advancements in antibody engineering and radiopharmaceutical development for enhanced cancer targeting.
Main Methods:
- Review of ongoing clinical trials for immunotherapy and RIT in NHL.
- Analysis of emerging antibody engineering techniques, including bivalent antibodies and fusion proteins.
- Examination of pretargeting strategies for improved radionuclide delivery in cancer therapy.
Main Results:
- Immunotherapy and RIT demonstrate high response rates and favorable safety profiles in relapsed/refractory NHL.
- Antibody engineering innovations offer enhanced targeting specificity and novel therapeutic constructs.
- Pretargeting approaches aim to reduce systemic radiation exposure and allow higher therapeutic doses.
Conclusions:
- The molecular understanding of NHL is driving significant therapeutic advancements.
- Immunotherapy, RIT, and advanced antibody-based strategies represent promising avenues for NHL treatment.
- Continued innovation in radiopharmaceutical development, including pretargeting, is expected to improve patient outcomes.
